Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
作者信息
Ghoti Hussam, Fibach Eitan, Merkel Drorit, Perez-Avraham Galit, Grisariu Sigal, Rachmilewitz Eliezer A
出版信息
Haematologica. 2010 Aug;95(8):1433-4. doi: 10.3324/haematol.2010.024992. Epub 2010 Apr 26.
Abstract
摘要
相似文献
1
Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
Haematologica. 2010 Aug;95(8):1433-4. doi: 10.3324/haematol.2010.024992. Epub 2010 Apr 26.
2
Delineating parameters of iron overload in MDS patients treated with deferasirox.
Leuk Res. 2010 Dec;34(12):1556-7. doi: 10.1016/j.leukres.2010.06.032. Epub 2010 Aug 17.
3
Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Br J Haematol. 2011 Apr;153(1):118-20. doi: 10.1111/j.1365-2141.2011.08587.x. Epub 2011 Feb 20.
4
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
Eur J Haematol. 2012 Mar;88(3):260-8. doi: 10.1111/j.1600-0609.2011.01726.x. Epub 2011 Nov 24.
5
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
Leuk Res. 2010 Dec;34(12):1560-5. doi: 10.1016/j.leukres.2010.06.013. Epub 2010 Jul 8.
6
Iron chelation therapy in myelodysplastic syndrome - Cui bono?
Leukemia. 2009 Aug;23(8):1373. doi: 10.1038/leu.2009.39.
7
Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
J Clin Pharm Ther. 2016 Feb;41(1):59-63. doi: 10.1111/jcpt.12348. Epub 2016 Jan 18.
8
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.
9
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
Oncologist. 2009 May;14(5):489-96. doi: 10.1634/theoncologist.2008-0154. Epub 2009 Apr 13.
10
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
Br J Haematol. 2009 Dec;147(5):752-9. doi: 10.1111/j.1365-2141.2009.07908.x. Epub 2009 Sep 18.
引用本文的文献
1
New Approaches and Strategies for the Repurposing of Iron Chelating/Antioxidant Drugs for Diseases of Free Radical Pathology in Medicine.
Antioxidants (Basel). 2025 Aug 10;14(8):982. doi: 10.3390/antiox14080982.
2
Increased ferroptosis of erythrocytes is associated with myelodysplastic syndromes.
Ann Hematol. 2024 Oct;103(10):4009-4020. doi: 10.1007/s00277-024-05946-y. Epub 2024 Aug 23.
3
The Effect of Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes: A Study by the Israeli MDS Working Group.
Acta Haematol. 2024;147(4):427-434. doi: 10.1159/000535749. Epub 2023 Dec 16.
4
A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
Cells. 2023 Feb 16;12(4):633. doi: 10.3390/cells12040633.
5
Understanding the Potential and Risk of Bacterial Siderophores in Cancer.
Front Oncol. 2022 Jun 17;12:867271. doi: 10.3389/fonc.2022.867271. eCollection 2022.
6
Congenital sideroblastic anemia model due to ALAS2 mutation is susceptible to ferroptosis.
Sci Rep. 2022 May 30;12(1):9024. doi: 10.1038/s41598-022-12940-9.
7
Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes.
Blood Adv. 2022 Jun 14;6(11):3551-3555. doi: 10.1182/bloodadvances.2021006277.
8
Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia.
Cells. 2021 Mar 26;10(4):734. doi: 10.3390/cells10040734.
9
The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Front Immunol. 2021 Feb 19;11:627662. doi: 10.3389/fimmu.2020.627662. eCollection 2020.
10
Protein Carbonylation and Lipid Peroxidation in Hematological Malignancies.
Antioxidants (Basel). 2020 Dec 1;9(12):1212. doi: 10.3390/antiox9121212.
本文引用的文献
1
Iron: The fifth horseman of the apocalypse?
Am J Hematol. 2009 May;84(5):263-4. doi: 10.1002/ajh.21413.
2
Myelodysplasia paranoia: iron as the new radon.
Leuk Res. 2009 Sep;33(9):1158-63. doi: 10.1016/j.leukres.2008.10.017. Epub 2008 Nov 25.
3
Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.
Eur J Haematol. 2007 Dec;79(6):463-7. doi: 10.1111/j.1600-0609.2007.00972.x. Epub 2007 Nov 1.
4
Intracellular labile iron.
Int J Biochem Cell Biol. 2008;40(3):350-4. doi: 10.1016/j.biocel.2007.03.010. Epub 2007 Mar 19.
5
Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants.
Br J Haematol. 2006 Jan;132(1):108-13. doi: 10.1111/j.1365-2141.2005.05834.x.
6
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
J Clin Oncol. 2005 Oct 20;23(30):7594-603. doi: 10.1200/JCO.2005.01.7038. Epub 2005 Sep 26.
7
Management of anemia associated with myelodysplastic syndrome.
Semin Hematol. 2005 Apr;42(2 Suppl 1):S10-3. doi: 10.1053/j.seminhematol.2005.01.002.
8
LPI-labile plasma iron in iron overload.
Best Pract Res Clin Haematol. 2005 Jun;18(2):277-87. doi: 10.1016/j.beha.2004.10.003.
9
Myelodysplastic syndromes.
Hematology Am Soc Hematol Educ Program. 2002:136-61. doi: 10.1182/asheducation-2002.1.136.
10
Redox state of glutathione in human plasma.
Free Radic Biol Med. 2000 Feb 15;28(4):625-35. doi: 10.1016/s0891-5849(99)00275-0.
Zotero 插件